Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hagop Kantarjian, M.D.
University of Texas, MD Anderson Cancer Center, Houston, TX 713-792-7026 hkantarj@mdanderson.org
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Charite University of Medicine
Berlin, Germany
- Johann Wolfgang Goethe Universität
Frankfurt am Main, Germany
- University of Heidelberg Medical Clinic
Mannheim, Germany
- Chaim Sheba Medical Center
Tel Litwinsky, Israel
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2006
- Primary completion
- 31 May 2008
- Completion
- 31 May 2008
- Last update posted
- 1 Jun 2009
- Registered enrollment
- 100
- Registry id
- NCT00352677
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.